Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: Higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45

American Journal of Surgical Pathology

Volumn 25, Issue 8, 2001, Pages 1039-1046

  Shidham, Vinod B ^a   Qi, Dan Yi ^a   Acker, Scott ^a   Kampalath, Bal ^a   Chang, Chung Che ^a   George, Varghese ^b   Komorowski, Richard ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Division of Biostatistics   (United States)

Author keywords

HMB 45; Lymphadenectomy; MART 1; Melan A; Melanoma; Micrometastasis; PG M1; S 100 protein; Sentinel lymph node

Indexed keywords

MELAN A; MONOCLONAL ANTIBODY HMB 45; PROTEIN S 100; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SENTINEL LYMPH NODE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; ROC CURVE; S100 PROTEINS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 0034928853     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200108000-00008     Document Type: Article

References (49)

1. Metastatic melanoma in lymph nodes: Relative sensitivities of 5 melanoma antibodies
2. HMB-45 immunohistochemical staining of sentinel lymph nodes: A specific method for enhancing detection of micrometastases in patients with melanoma
3. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
4. Effusion cytology of malignant melanoma: A morphologic and immunocytochemical analysis including application of the MART-1 antibody
5. The use of relative operative characteristic (ROC) curves in test performance evaluation
6. Sentinel lymph node evaluation in melanoma
7. Melan-A, a new melanocytic differentiation marker
8. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial. WHO Melanoma Programme
9. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: A comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A)
10. Occult melanoma in lymph nodes detected by antiserum to S-100 protein
11. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma
12. A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
13. The case against elective lymphadenectomy
14. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma
15. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
16. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells
17. Receiver operating characteristic (ROC) methodology: The state of the art
18. Detection of submicroscopic lymph node metastases in patients with melanoma
19. T311: An anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues
20. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues
21. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tumor
22. Production of recombinant MART-I proteins and specific anti-MART-I polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1
23. Intraoperative identification of sentinel lymph node in patients with malignant melanoma
24. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves
25. Pathologic examination of the sentinel lymph node
26. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: Comparison with four other melanoma markers
27. The tumor biology of melanoma nodal metastases
28. Technical details of intraoperative lymphatic mapping for early stage melanoma
29. 'Histiocytic markers' in melanoma
30. Significance of occult metastasis: A study of breast cancer
31. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma
32. Detection of melanoma micrometastases in sentinel lymph nodes: Evaluation of MART-1 and Melan-A in comparison to traditionally used immunomarkers
33. Pathology and probability: Likelihood ratios and receiver operating characteristic curves in the interpretation of bronchial brush specimens
34. Diagnostic accuracy in cytopathology
35. The orderly progression of melanoma nodal metastases
36. Recent advances in the care of the patient with malignant melanoma
37. Nevus cell aggregates associated with lymph nodes: Estimated frequency and clinical significance
38. The case for elective lymphadenectomy
39. Obscure axillary lymph node metastasis in carcinoma of the breast
40. Monoclonal antibody MAT-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections
41. Detection of melanoma metastases in lymph nodes using three different monoclonal antibodies
42. Intraoperative scrape cytology: Comparison with frozen section using probabilistic statistical method
43. The role of sentinel lymph node mapping for melanoma
44. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma
45. The immunocytochemical detection of axillary micrometastases in breast cancer
46. The pathology of melanoma patients with negative sentinel nodes who subsequently develop ipsilateral nodal metastasis
47. Probability in lymph node sampling
48. Detection of microscopic melanoma metastases in sentinel lymph nodes